Literature DB >> 31046091

Ovarian cancer suspicion, urgent referral and time to diagnosis in Danish general practice: a population-based study.

Marie-Louise L Baun1,2, Henry Jensen1, Alina Z Falborg1, Hanne N Heje1, Lone K Petersen3, Peter Vedsted1.   

Abstract

BACKGROUND: Ovarian cancer (OC) survival rates are lower in Denmark than in countries with similar health care. Prolonged time to diagnosis could be a contributing factor. The Danish cancer patient pathway (CPP) for OC was introduced in 2009. It provides GPs with fast access to diagnostic work-up.
OBJECTIVE: To investigate cancer suspicion and pathway use among GPs and to explore the association between these factors and the diagnostic intervals (DIs).
METHODS: We conducted a national population-based cohort study using questionnaires and national registers.
RESULTS: Of the 313 women with participating GPs, 91% presented with symptoms within 1 year of diagnosis, 61% presented vague non-specific symptoms and 62% were diagnosed with late-stage disease. Cancer was suspected in 39%, and 36% were referred to a CPP. Comorbidity [prevalence ratio (PR): 0.53, 95% confidence interval (CI): 0.29-0.98] and no cancer suspicion (PR: 0.35, 95% CI: 0.20-0.60) were associated with no referral to a CPP. The median DI was 36 days. Long DIs were associated with no cancer suspicion (median DI: 59 versus 20 days) and no referral to a CPP (median DI: 42 versus 23 days).
CONCLUSIONS: Nine in ten patients attended general practice with symptoms before diagnosis. Two-thirds initially presented with vague non-specific symptoms were less likely to be referred to a CPP and had longer DIs than women suspected of cancer. These findings underline the importance of supplementing the CPP with additional accelerated diagnostic routes.
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Denmark; general practice; ovarian neoplasms; referral; symptom assessment; time to diagnosis

Mesh:

Year:  2019        PMID: 31046091     DOI: 10.1093/fampra/cmz013

Source DB:  PubMed          Journal:  Fam Pract        ISSN: 0263-2136            Impact factor:   2.267


  6 in total

1.  Mode of Referral of Ovarian Cancer Patients: Does it Alter Treatment and Survival?

Authors:  Anas Barakat; Aemn Ismail; Quentin Davies; Supratik Chattopadhyay
Journal:  In Vivo       Date:  2022 Jul-Aug       Impact factor: 2.406

2.  Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015-2016.

Authors:  Yngvar Nilssen; Odd Terje Brustugun; Morten Tandberg Eriksen; Erik Skaaheim Haug; Bjørn Naume; Bjørn Møller
Journal:  BMC Cancer       Date:  2020-05-30       Impact factor: 4.430

3.  Role of primary care physician factors on diagnostic testing and referral decisions for symptoms of possible cancer: a systematic review.

Authors:  Victoria Hardy; Adelaide Yue; Stephanie Archer; Samuel William David Merriel; Matthew Thompson; Jon Emery; Juliet Usher-Smith; Fiona M Walter
Journal:  BMJ Open       Date:  2022-01-24       Impact factor: 2.692

4.  Diagnosing pancreatic cancer in general practice: a cross-sectional study on associations between suspicion of cancer, urgent referral and time to diagnosis.

Authors:  Line F Virgilsen; Linda A Rasmussen; Peter Vedsted; Henry Jensen
Journal:  Scand J Prim Health Care       Date:  2022-02-11       Impact factor: 3.147

5.  Factors impacting the time to ovarian cancer diagnosis based on classic symptom presentation in the United States.

Authors:  Sarah P Huepenbecker; Charlotte C Sun; Shuangshuang Fu; Hui Zhao; Kristin Primm; Sharon H Giordano; Larissa A Meyer
Journal:  Cancer       Date:  2021-08-04       Impact factor: 6.860

6.  Direct access from general practice to transvaginal ultrasound for early detection of ovarian cancer: a feasibility study.

Authors:  Marie-Louise Ladegaard Baun; Margit Dueholm; Hanne Nørgaard Heje; William Hamilton; Lone Kjeld Petersen; Peter Vedsted
Journal:  Scand J Prim Health Care       Date:  2021-06-07       Impact factor: 2.581

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.